NR4A1 and breast carcinoma: The expression levels of NR4A1 decreased in patients with recurred (tamoxifen-resistant) luminal A type breast cancer treated with tamoxifen therapy (GSE1378) and hormone therapy (METABRIC) compared to those in patients with non-recurred (tamoxifen-sensitive) luminal A type breast cancer (Figure 1C,D).